Novel therapies for DCM are the No. 7 priority explored by Michelle and Ben. Ricardo Rodrigues-Pinto outlines our current limitations and the potential spectrum of advances, from biological treatments to assistive technologies. Annie Wandycz shares her lived experience of therapies for DCM, her frustrations and optimism, and her helpful perspectives from the online support group. Mark Kotter explains how novel experimental treatment paradigms can deliver progress in both laboratory and clinical settings, and Julio Furlan describes how strategies for neurorehabilitation in spinal cord injury could advance the DCM field.
Episode link: [ Ссылка ]
(video made with Headliner.app)
